Introduction
Abnormalities in prostatic speci®c antigen or digital rectal examination usually lead the patient to transrectal ultrasound of the prostate and biopsy. At that time, tissue is obtained and sent for histological examination. A certain percentage of patients, ranging from 5.5% to 19% will be diagnosed with prostatic intraepithelial neoplasia (PIN). 1, 2 It has been suggested that microscopically normal prostate tissue, low grade PIN, high grade PIN, and early invasive prostate cancer can be looked at as a continuum of histological changes. 3 These changes are characterized by basal cell layer disruption, progressive loss of markers of secretory differentiation, increasing nuclear and nucleolar abnormalities, increasing proliferative potential and increasing variation of DNA content. 3 With all the changes noted above, high grade PIN will continue to reside on an intact basal cell layer. Once this layer has been violated, early invasive prostate cancer exists. 3 Of 195 radical prostate specimens removed for prostate cancer, microscopically PIN was present 86% of the time. 4 In 64.5%, it was multicentric and 63% of the time PIN was found in the peripheral zone. 4 The total volume of PIN increased with progression of Gleason's score and pathological stage. It was concluded that, because the general distribution of both prostate cancer and PIN were so closely related, this supports the hypothesis that PIN is a precursor of prostate cancer. 4 Bostwick in further reviews indicates that PIN alone has an increased risk of 15-fold above patients without PIN as a predictor of prostate cancer. It was recommended that patients with PIN on biopsy diagnosis be treated as if coexistent prostate cancer is always present. The increased predictive value of high grade PIN as a marker for prostate cancer warrants a further search for concurrent invasive cancer. 3, 5 Noting the signi®cance of high grade PIN relative to the future development of prostate cancer, we reviewed the charts of 130 patients diagnosed as having PIN to assess compliance with follow-up recommendations for future re-biopsy.
Materials and methods
Biopsy results from our community hospital obtained during the time period of June 1993 to June 1996 were reviewed for histological evidence of PIN. The initial biopsy was performed due to abnormalities in PSA, digital ± rectal examination, transrectal ultrasound or PSA density. Patients ranged in age from 45 to 79 y of age. Sextant biopsies were performed with a biopsy gun under ultrasound guidance and sent separately to pathology for microscopic diagnosis. Since the diagnosis of PIN is a relatively new entity, the diagnosis was made after review of the slides by three Board Certi®ed pathologists. Patients were informed of their diagnosis 3 ± 6 days after the procedure.
Within this time frame, 130 patients undergoing prostate biopsy had pathological changes consistent with high grade PIN. All patients were informed by phone of this diagnosis on obtaining results and instructed that additional biopsy material would be needed from 6 ± 12 months later. Included in this phone discussion were the increased risks of prostate cancer as it relates to PIN. In addition to the telephone conversation with the patient, a letter was sent to the patient's home address with the recommendation for re-biopsy. Finally, a letter was sent to the referring physician summarizing the patient's pathological diagnosis of PIN and recommending that rebiopsy be performed within 6 ± 12 months. Patients failing to follow-up received a certi®ed letter and a phone call when their repeat biopsy date had passed.
Charts were reviewed retrospectively and an end date of 30 June 1996, was chosen to give any patient diagnosed with PIN by that date a chance to follow-up by 31 July 1997. Original biopsy date and pathological diagnosis were recorded as well as any subsequent biopsy date and ®ndings. No patient died prior to their initial followup date.
Results
From June 1993 to July 1996, 130 patients had biopsy results consistent with high grade PIN. Patient follow-up was broken down into time periods based on the time of their repeat biopsy date. Time periods were classi®ed into follow-up in 6 ± 12 months, b12 months to 18 months, and b18 months, as well as no follow-up. Table 1 reveals the patient breakdown within these groups. Only 39 patients (30%) returned for re-biopsy within 12 months, 36 patients (28%) by 18 months, 11 patients (8%) after 18 months, and 44 patients (34%), the largest single group, never returned for their repeat biopsy. When this group is looked at as a whole, only 30% of patients (39/130 patients) returned for follow-up as recommended, ie rebiopsy in 6 ± 12 months.
The pathological diagnoses on follow-up biopsy are seen in Table 2 . A total of 86 of 130 patients with an initial diagnosis of PIN returned for follow-up evaluation. On repeat biopsy, one of 86 patients had a biopsy that was suspicious but not diagnostic of prostate cancer. Six of 86 patients (7%) were not re-biopsied. In this group, rebiopsy was not accomplished because of failure of the patient to follow preoperative instructions. Fourteen of 86 patients (16%) had adenocarcinoma of the prostate. Twenty-one of 86 patients (24%) had PIN. Forty-four of 86 patients (51%) had benign prostatic hyperplasia. This group of patients with benign prostatic hyperplasia were scheduled for reevaluation in 12 months. In summary, patients with an initial diagnosis of PIN on re-biopsy were found to have cancer 16% of the time and persistent PIN 24% of the time. Fifty-one percent were found to have benign prostatic hyperplasia.
Discussion
Yearly PSA evaluation and digital ± rectal examination of men at risk for developing prostate cancer are aimed at trying to detect disease at an earlier and, therefore, theoretically curable stage. Abnormalities in PSA, digital rectal examination, transrectal ultrasound of the prostate, PSA density and/or PSA velocity are all suggestive, but not diagnostic of prostate cancer. Recently it has been postulated that the presence of PIN on prostate biopsy specimens places the patient at greater risk of having coexistent prostate cancer and/or developing prostate cancer in the future. 3 With microscopic changes in the development of prostate cancer seen as a continuum from normal tissue progressing to high grade PIN to ultimate early invasive cancer of the prostate, we now have available another factor that may allow earlier detection of prostate cancer if monitored and followed properly when found at the time of initial prostate biopsy. This diagnosis of PIN in itself is not a basis for therapeutic decisions but Patient follow-up after PIN diagnosis TJ Maatman et al strongly suggests that the patient with PIN be followed closely and re-biopsied for future detection of prostate cancer. A recent multicenter study found PIN in 9 ± 16% of 400 prostate biopsy specimens. 6 This represents a signi®cant proportion of patients that need close monitoring. Several studies have gone on to show the importance of repeat biopsy in men initially found to be have PIN. Between 35 and 51% of men with an initial diagnosis of PIN will subsequently be found to have prostate cancer on subsequent biopsies. 7 ± 10 Finally, the importance of continued surveillance with repeat biopsy is shown by the incidence of cancer detected on ®rst, second, and third repeat biopsy in men with initial diagnosis of PIN. 11 Initially, when PIN was described, no speci®c time for re-biopsy was suggested. In the current study, repeat biopsy is recommended at 6 ± 12 months following the initial diagnosis of PIN. We found that in men presenting for re-biopsy, the prostate cancer detection rate was 14 of 86 patients of 16%, signi®cantly lower than the expected 35 ± 51%. Since only 39 of 130 patients, or 30% of the men, followed the recommendation and presented for rebiopsy within the speci®ed time frame, it is apparent that non-compliance contributes to the lower cancer detection rate on repeat biopsy of these men. It should be noted that 44 of 130 patients, or 33.8% of the patients in the study, failed to return for follow-up biopsy. Current recommendations for following men with an initial diagnosis of PIN range from re-biopsy in 3 ± 6 months to biopsy every 6 months for 2 y and yearly thereafter. 12 ± 14 Others have suggested immediate biopsy when PIN is found. 2, 15 Perhaps a standard recommendation that can be agreed upon by all will soon be established for rebiopsy of men with an initial diagnosis of PIN. If a standard protocol can be adopted, the non-compliance record can be more formally addressed. Currently we recommend re-biopsy within 6 ± 12 months if PIN is found on the initial biopsy. The recommendation is made orally to the patient by telephone and in writing to both the patient and referring physician. If the patient fails to comply, he is contacted by telephone and certi®ed letter reminding him of the importance of the relationship of PIN and the future development of adenocarcinoma of the prostate and the need for re-evaluation with transrectal ultrasound of the prostate and biopsy.
With this protocol, only 39 of 130 men (30%) of the patients complied and presented for re-biopsy within the recommended time frame. An additional 36 of 130 men (27.7) responded and were re-biopsied within 18 months from the initial diagnosis of PIN. Eleven of 130 patients (8.46%) were re-biopsied greater than 18 months after the ®rst biopsy. Forty-four of 130 patients (33.8%) were lost to follow-up.
We found by direct nurse and physician questioning of non-compliant patients that there are numerous reasons why patients do not return for recommended follow-up re-biopsy. Table 3 lists some of these reasons. The procedure itself performed without anesthesia may be too uncomfortable for some patients to want to repeat. Some patients may fear the diagnosis of prostate cancer. Of concern, however, is the possible ineffective communication to the patient of the importance of the relationship of PIN and co-existent presence of cancer of the prostate and future development of prostate cancer.
In summary, numerous studies have shown that high grade PIN is a histological abnormality one step away from early invasive prostate cancer. PIN has also been shown to co-exist with prostate cancer. If the goal is to diagnose and treat prostate cancer while it is contained, ie early stage disease, it is important to use all diagnostic abilities available, including PSA, digital ± rectal examination, and transrectal ultrasound of the prostate. In addition, the diagnosis of PIN is an absolute indication that pre-cancerous changes are occurring within the prostate and the surgeon must recognize the signi®cance of this and implement and appropriate follow-up protocol. This, in turn, must be conveyed effectively to the patient to insure patient awareness and reduce patient non-compliance. A standard protocol of follow-up biopsy in patients with an initial diagnosis of PIN and improved patient compliance will undoubtedly result in an increase in prostate cancer detection.
